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Abstract
Background: Human Papillomavirus (HPV) is the most common sexually transmitted infection. In Italy, HPV
vaccination is now offered free of charge to 12-year-old females. However, some regional health authorities have
extended free vaccination to other age-groups, especially to girls under 18 years of age. We conducted a multicentre
epidemiological study to ascertain the prevalence of different genotypes of HPV in young Italian women with normal
cytology, with the aim of evaluating the possibility of extending vaccination to older females.
Methods: The study was performed in 2010. Women aged 16–26 years with normal cytology were studied. Cervical
samples were analyzed to identify the presence of HPV by PCR amplification of a segment of ORF L1 (450 bp).
All positive HPV-DNA samples underwent viral genotype analysis by means of a restriction fragment length
polymorphism assay.
Results: Positivity for at least one HPV genotype was found in 18.2% of the 566 women recruited: 48.1% in the 16–17
age-class, 15.4 in the 18–20 age-class, 21.9% in the 21–23 age-class, and 15.5% in the 24–26 age-class; 10.1% of women
were infected by at least one high-risk HPV genotype. HPV-16 was the most prevalent genotype. Only 4 (0.7%), 4 (0.7%)
and 3 (0.5%) women were infected by HPV-18, HPV-6 and HPV-11, respectively. Of the HPV-DNA-positive women, 64.1%
presented only one viral genotype, while 24.3% had multiple infections. The HPV genotypes most often involved in
multiple infections were high-risk. A high prevalence was noted in the first years of sexual activity (48.1% of HPV-DNA-
positive women aged 16–17 years); HPV prevalence subsequently declined and stabilized.
The estimate of cumulative proportions of young women free from any HPV infection at each age was evaluated;
93.3% and 97.1% of 26 year-old women proved free from HPV-16 and/or HPV-18 and from HPV-6 and/or HPV-11,
respectively.
Conclusions: Our findings confirm the crucial importance of conducting studies on women without cytological
damage, in order to optimise and up-date preventive interventions against HPV infection, and suggest that vaccinating
26-year-old females at the time of their first pap-test is to be recommend, though this issue should be further explored.
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Background
Many types of human papillomavirus (HPV) are known.
Of these, about 50 have a high tropism for the ano-genital
mucosa and are sexually transmitted. According to the
most recent classification of the International Agency for
Research on Cancer (IARC) 12 genotypes are defined as
high-risk (HR) oncogenic (HPV-16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, and 59). Moreover, a probable oncogenic
risk has been assigned to genotype 68, and a possible
oncogenic risk to the types: HPV-26, 53, 66, 67, 70, 73, 82,
30, 34, 69, 85, and 97. Many low-risk (LR) genotypes that
cause benign lesions and warts are also known (HPV 6,
11, 28, 32, 40, 42, 43, 44, 54, 55, 57, 61, 62, 71, 72, 74, 81,
83, 84, 86, 87, and 89) [1].
After zur Hausen’s discovery of the association be-
tween persistent infection by oncogenic types of HPV
and cervical cancer [2], epidemiological studies and ex-
perimental research into the development of preventive
vaccines began. Since that time, our knowledge of the
virus in subjects with HPV-associated lesions has in-
creased, revealing the great complexity of the ecosystem
of this pathogen [3-5].
The prevalence of HPV in subjects with lesions dis-
plays a different distribution by region and age [6-9].
The first epidemiological data were obtained in the
United States [10-14]. Subsequently, many observations
were collected in the rest of the world [15,16]. Several
studies have also been conducted in Europe and in Italy
[17-24].
So far, two HPV vaccines have been licensed: a bivalent
vaccine (Cervarix® GlaxoSmithKline Biologicals S.A.) and
a quadrivalent vaccine (Gardasil® Merck and Co). Both
have a prophylactic indication and are able to prevent
pre-cancerous lesions and cancers due to persistent in-
fection by HPV-16 and HPV-18. Furthermore, both vac-
cines have been shown to elicit cross-protection against
other high-risk HPV types [25,26]. Gardasil® also offers
protection against genital warts and low-risk lesions
caused by HPV-6 and HPV-11.
The epidemiological data collected worldwide consti-
tute the starting point for vaccination strategies. How-
ever, in order to draw up optimal vaccination policies, it
is crucial to know the prevalence of the different HPV
types in the overall population, and not only in subjects
with lesions or cancer. Indeed, such knowledge is essen-
tial to predicting the expected impact and monitoring
the actual impact of HPV immunisation. For this reason,
several extensive studies on women with normal cy-
tology have been conducted [7,27-29].
The World Health Organization and the European
Centre for Disease Prevention and Control recommend
HPV vaccination and indicate young females (aged 10–
14 years) as the target population [30,31]. In Europe, al-
most every country offers vaccination free of charge to
females aged 11–12 years [32]. Since 2008, HPV vaccin-
ation has been offered free of charge to 12-year-old fe-
males in Italy, and 70.6% of eligible subjects belonging
to the first vaccinated cohort (females born in 1997)
have been immunized with at least one dose [33].
Two years after the start of HPV vaccination, we con-
ducted a multicentre epidemiological study to ascertain
the prevalence of different genotypes of HPV in young
Italian women with normal cytology, with a view to evalu-
ating the possibility of extending vaccination – for in-
stance by offering free vaccination to 26-year-old females.
Methods
The study protocol, which was used by all research
units, was approved by the Ethics Committee of the
Local Healthcare Unit (LHU) in Genoa, Italy.
The study was performed in 2010 and enrolment was
carried out during the first six months of the year.
Study population
The study population was recruited in three cities in
northern Italy (Turin, Milan and Genoa).
The study protocol involved enrolling all consecutive
eligible young women aged 16–26 years who spontan-
eously accessed gynaecology centres of the LHUs for med-
ical consultations from 1st January to 30th June 2010. We
chose this age-group because it is potentially the best tar-
get for vaccination. Written informed consent was ob-
tained from every participant. Women were considered
eligible for enrolment if they were sexually active, were
not pregnant, had not been vaccinated against HPV and
had no previous history of cervical abnormalities.
All participants underwent a Pap smear and HPV-
DNA test. Subsequently, only women with normal cyto-
logically negative Pap smears were studied, as the aim of
the study was to evaluate the prevalence of HPV geno-
types in healthy young women without any HPV lesions.
Women with a positive pap smear were excluded from
the study. They were followed up by the gynaecology
centres of the LHUs or by their own gynaecologists and
were treated in accordance with the Italian guidelines
[34]. No data on these women were supplied to the re-
searchers involved in this study.
Sample collection
Cervical samples were collected by means of a spatula,
immersed and rinsed in a vial containing 20 ml of Pre-
servCyt® solution (ThinPrep Pap Test, Hologic, Italy)
and stored at room temperature (RT) until processing.
All samples were analysed in the molecular laboratory of
the Department of Biomedical Sciences for Health –
University of Milan.
Ten millilitres of each PreservCyt® solution containing
cervical cells was centrifuged at 3800 g for 10 min at
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RT. Cellular pellets were resuspended in 1 ml Phosphate
Buffered Saline (PBS) and stored at −20°C until molecu-
lar analyses were carried out.
DNA extraction and HPV detection
DNA was extracted from cervical samples by means of a
commercial method (NucliSENS® EasyMAG®, bioMér-
ieux, Lyon, France) according to the manufacturer’s in-
structions. The concentration and purity of the DNA
extracted were evaluated by means of a spectrophotom-
eter (Thermo Scientific NanoDrop 2000; Thermo Fisher
Scientific Inc., Wilmington, DE). DNA integrity was
assessed by amplification of a 268 base pair (bp) frag-
ment in the ubiquitous β-globin gene by using the pri-
mer pair PCO4 and GH20 [35].
HPV DNA was detected by PCR amplification of a
450 bp segment of ORF L1 by using the degenerate pri-
mer pair ELSI-f and ELSI-r, as previously described [36].
Each PCR run included positive controls (DNA ex-
tracted from HPV 16-positive cells, CaSki) and negative
(water) controls. The amplification products were visual-
ized by means of electrophoresis analysis on 2% agarose
gels containing ethidium bromide (0.5 mg/ml). Ampli-
fied product bands were compared with molecular
weight standards (DNA Molecular Weight, Marker 100,
Sigma-Aldrich, St. Louis, MO).
Restriction fragment length polymorphism (RFLP)
genotype analysis
All amplified fragments were subjected to viral genotype
analysis by RFLP capable of identifying all HR, probable/
possible HR, and LR genotypes of the alpha genus ac-
cording to the new IARC classification system [1,37].
Amplified products (1 g each) were added to three dif-
ferent digestion solutions, each containing 1U of either
RsaI, DdeI or HaeIII (New England BioLabs, Ipswich,
MA) restriction enzymes diluted in their respective
buffers for 1 h at 37°C. The digestion products were
identified following separation in 3% agarose gels, and
restriction patterns were compared with appropriate
standards (DNA Molecular Weight, Marker 100 + 20,
Sigma-Aldrich, St. Louis, MO). The pattern of fragments
generated by the three restriction enzymes enabled the
genotype to be identified [38,39].
Samples displaying complex or undetermined RFLP
patterns were retested. Samples that could not be
assigned with confidence to a certain type after two con-
secutive analyses were classified as “not typing” (NT).
Statistical analysis
The prevalence of HPV-infected cases, together with
their 95% Confidence Intervals (CI), was described by
age-class and city of residence, and the Chi-square test
was used to analyze the differences (a two-sided p-value
< 0.05 was considered statistically significant). The sub-
jects enrolled were broken down into 4 age-classes: 16–
17, 18–20, 21–23 and 24–26 years old. In addition, the
percentage of infections, broken down by risk-group in
the different age-classes, was calculated on considering
the total number of infections detected in each age-
class.
The Kaplan-Meier method was used to estimate the
cumulative proportions of young females who were free
from HPV infection at each age, and graphic descrip-
tions of all HPV genotypes and different HPV genotypes
were drawn up. All analyses were performed with the
Statistical Package for Social Sciences, for Windows, ver-
sion 16.0 (SPSS, Inc., Chicago, Illinois).
Results
A total of 650 women who met the inclusion criteria
were invited to participate in the study; 16 declined. As
few women refused to participate, the reasons for refusal
were not investigated.
Of the 634 young women who agreed to take part in
the study, 566 with normal cervical cytology were re-
cruited. The 68 who were excluded had a positive Pap
smear. In Milan, Genoa and Turin 281, 156 and 129
subjects were enrolled, respectively. Table 1 shows the
demographic characteristics of the study population.
The mean age of the participants on enrolment was
19.7 years (SD = 2.4). Positivity for at least one HPV geno-
type was found in 103 women (18.2%; 95% CI 10.7-25.6).
In Milan, Genoa and Turin, 16.0% (95% CI 11.3-20.8),
24.4% (95% CI 17.8-31.9) and 15.5% (95% CI 9.3-22.9) of
women, respectively, were HPV-positive. No statistically
significant differences emerged among the cities of resi-
dence (p = 0.064). Among the 103 HPV-DNA-positive
women, the samples from 12 subjects (11.6%) were NT.
Regarding high-risk HPV types, fifty-seven women
(55.3%) were infected by at least one high-risk HPV geno-
type. HPV-16 was the most prevalent genotype, being de-
tected in 16 women (15.5%). Only 4 subjects (3.9%) were
infected by HPV-18. Sixty-six subjects (64.1%) presented
only one viral genotype, while 25 (24.3%) had multiple
infections. Globally, 132 HPV infections were detected in
the 103 HPV DNA-positive women. Figure 1 shows all the
HPV genotypes detected and highlights the relevance of the
Table 1 Demographic characteristics of the study
population
Age-class (years) Milan Genoa Turin Total
16-17 2 25 0 27
18-20 247 70 59 376
21-23 17 41 47 105
24-26 15 20 23 58
Total 281 156 129 566
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various genotypes in relation to the total number of infec-
tions. With regard to high-risk genotypes HPV-16 was most
frequently detected, followed by HPV-52 and HPV-56.
Regarding the importance of the different genotypes
on considering the infection type (single or multiple) we
found that most of the single infections were caused by
high-risk or probable/possible high-risk HPV genotypes
(74.2%). Concomitant HPV-16 and HPV-18 infections
were not found.
Figure 2 shows the distribution of multiple infections
on the basis of HPV combinations. It can be seen that
the most frequent multiple infections were sustained by
high-risk genotypes combined with probable/possible
high-risk genotypes (28%). The most frequent HPV in-
volved in multiple infections was HPV-16 (16%),
followed by: HPV-52 (12%), HPV-53 (8%), HPV-58 (8%)
and HPV-56 (6%).
Regarding low-risk HPV types, HPV-40 was the ge-
notype most often detected. Only 4 (3.9%) and 3 (2.9%)
women were infected by HPV-6 and HPV-11, respect-
ively. Of 25 multiple infections, only one was caused
exclusively by low-risk HPV genotypes (HPV-6 and
HPV-11 together).
Table 2 shows the prevalence of subjects positive for
at least one HPV type, broken down by age-class. The
difference in prevalence among the different age-classes
Figure 1 Percentages of all genotypes detected on considering the total number of infections.
Figure 2 Distribution of multiple infections on the basis of
HPV combinations. H+H: double infection by two high-risk HPVs;
H+L: double infection by one high- and one low-risk HPVs; L+L:
double infection by two low-risk HPVs; H+P: double infection by one
high- and one probable/possible-risk HPVs; L+P: double infection by
one low- and one probable/possible-risk HPVs; H+H+P: triple
infection by two high-risk and one probable/possible-risk HPVs; H+H+L:
triple infection by two high-risk and one low-risk HPVs; P+P: double
infection by two probable/possible-risk HPVs.
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was highly significant (p < 0.0001). A particularly high
prevalence was noted in the first years of sexual activity
(48.1% of HPV-DNA-positive women in the 16–17 age-
class); this was seen to decline and stabilize in the sub-
sequent age-classes. Furthermore, a high prevalence of
multiple infections was also observed in the 16–17 age-
class; specifically, the distribution of the percentages of
multiple infections on the basis of age was: 11.1% (95%
CI 0–22.9) (16–17 age-class), 4.5% (95% CI 2.4-6.6)
(18–20 age-class), 2.8% (95% CI 0–6.0) (21–23 age-
class), and 3.4% (95% CI 0–8.1) (24–26 age-class).
Figure 3 shows the percentage of infections broken
down by risk-group in the different age-classes on con-
sidering the total number of infections detected in each
age-class. The percentage of high-risk HPV infections
was seen to increase with increasing age, while the per-
centages of the probable or possible high-risk and low-
risk HPV infections decreased with increasing age.
Figure 4 shows the estimate of cumulative proportions
of young women free from any HPV infection at each age.
Figure 5 shows the estimate of cumulative proportions
of women free from high-risk vaccine genotypes (HPV-16
and HPV-18), free from high-risk non-vaccine genotypes
and free from low-risk vaccine genotypes (HPV-6 and
HPV-11) by age; 93.3% and 97.1% of 26 year-old women
proved free from HPV-16 and/or HPV-18 and from HPV-
6 and/or HPV-11, respectively.
Discussion
Our study revealed that 18.2% of the sexually active fe-
males with normal cervical cytology were infected by at
least one HPV genotype; this result is consistent with data
obtained by other authors in women without lesions
[26,28]. In 2007, de Sanjosé et al. performed a meta-
analysis on worldwide HPV prevalence and genotype dis-
tribution in women with normal cytology. On examining
the data on young (< 25 years old) European women, they
found a prevalence of about 22%, which was similar to
Table 2 Prevalence of negative and positive subjects for
at least one HPV type, broken down by age-class
HPV-DNA
Age-class (years) Negative Positive Total
N° (%) N° (%) N° (%)
95% CI 95% CI
16-17 14 (51.9) 13 (48.1) 27 (100)
33.0-70.7 29.2-66.9
18-20 318 (84.6) 58 (15.4) 376 (100)
80.9-88.2 11.7-19.0
21-23 82 (78.1) 23 (21.9) 105 (100)
70.2-86.0 14.0-29.8
24-26 49 (84.5) 9 (15.5) 58 (100)
75.2-93.8 6.2-24.8
16-26 463 (81.8) 103 (18.2) 566
78.4-84.9 15.1-21.6
Figure 3 Percentages of infections broken down by risk-group in the different age-classes on considering the total number of infec-
tions detected in each age-class.




Figure 4 Estimated cumulative proportions of young females free from any HPV infection at each age.
(A)HPV Genotypes: 16/18
(B)HPV Non-vaccine A9 species:31/33/35/52/58
(C)HPV Non-vaccine A7 species:39/45/59/68 
(D)HPV Genotypes: 6/11
Age (Years) Age (Years)
Age (Years) Age (Years)
Figure 5 Estimated cumulative proportions of young females free from high-risk vaccine genotypes (HPV-16 and HPV-18) (A), free
from high-risk non-vaccine genotypes (B and C) and free from low-risk vaccine genotypes (HPV-6 and/or HPV-11) (D) at each age.
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that reported by Bruni et al. in the same age-group of
young European women [26,28].
A prevalence study on HPV infection in women aged
18–24 years was carried out in 2006–2007 in Italy. The
authors found a prevalence of HPV of about 30% and, on
considering only the high-risk genotypes, a prevalence of
approximately 20%. These values are higher than ours.
However, their study population included women with
normal cytology and women with cytological lesions. On
considering only the data from the women with negative
cytology, the authors found a prevalence of about 20%,
which is comparable to our findings [40].
We recorded a prevalence of high-risk HPV genotypes
of 10.1%, while Clifford et al. found a prevalence of
high-risk HPV genotypes of 5.2% in Europe. However,
these authors considered a very large age-range, namely
15–74 years [6].
Regarding the relative importance of different high-
risk HPV types, the 6 most important in our study were:
HPV-16, -52, -56, -31, -51, -18. Our results are similar,
but not identical, to those reported by other authors. In
Europe in 2005, Clifford et al. reported the following
high-risk HPV types: HPV-16, -31, -18, -56, -45 and −35
[6]; Bruni et al. reported the types HPV-16, -31, -18, -33,
-52 and -51 [28], and de Sanjosé, who considered the 5
most important types, reported HPV-16, -31, -18, -33
and -35 [26]. Our results seem to confirm the growing
importance of type 52 in Italy and Europe, as in other
parts of the world (North America, Africa and Asia)
[6,26,28]. Mollers et al., who assessed the prevalence of
genital HPV infections in a large cohort of sexually ac-
tive young women (16–29 years old) in the Netherlands,
found that the most prevalent high-risk HPV types were
HPV-16, -51 and -52. However, as these authors did not
perform cytological analyses, their study population in-
cluded healthy women and women with lesions [41].
Another study that provided robust baseline estimates
of the prevalence and distribution of HPV types among a
nationally representative sample of women (25–64 years
old) in England, prior to any impact of the National HPV
Immunisation Programme, indicated that the most fre-
quent HPV genotypes among subjects with normal cy-
tology were: HPV-16, -52, -31 and -45 [42]. These data
were confirmed by subsequent findings obtained by the
same authors in young females up to 24 years old [18].
Furthermore, in a recent Dutch study, HPV types 16, 52,
51 and 31 had the highest type-specific incidence rates
among young females (18–29 years old) in the pre-vaccine
era; the researchers did not consider the cytological status
of the study sample [43].
Among the HPV genotypes recently defined as prob-
able/possible high-risk, we most frequently identified
type 66, while among low-risk viruses type 40 was most
frequently identified.
Regarding multiple infections, which are associated with
a higher risk of developing high-degree precancerous le-
sions, we found a higher prevalence (24.3%) than other au-
thors [44,45]. For instance, in French women under
25 years of age undergoing routine gynaecological exami-
nations, Monsonego et al. found a prevalence of 9.3%, al-
though these women were not selected through the filter
of normal cytological findings [46]. The lower prevalence
observed by Monsonego et al. could be explained by the
fact that the mean age of the French women was probably
higher than that of the women in our sample [46].
In young women (20–29 years old) randomly selected
from a population of Danish women, Nielsen et al. found
a prevalence of multiple infections of 10.5% [47]. The
difference between our data and those of Nielsen et al.
could be explained by the fact that our subjects were
younger than those examined by the Danish authors.
Furthermore, in our study, although the subjects re-
cruited were not distributed homogeneously by age, the
highest percentage of multiple infections (11.1%, 95% CI
0–23.0) was seen among 16-17-year-old subjects. This
result is consistent with the data from the literature, and
could be explained by the sexual habits of younger
women and by the fact that they have less immune ex-
perience than older women [48,49].
We found statistically significant differences in the
HPV prevalence rates observed at different ages, a par-
ticularly high prevalence being noted in the first years of
sexual activity. In the subsequent age-classes, the preva-
lence declined and stabilized. These results are sup-
ported by substantial data that indicate that the first
HPV infections often occur soon after the first sexual
intercourse [50-53]. In our adolescent group (16–17 years
old), the prevalence of low-risk HPV infections was
higher than that of probable/possible risk and high-risk
HPV genotypes. The only multiple infection caused ex-
clusively by HPV low-risk genotypes (HPV-6 and HPV-
11 together) was detected in a 16-year-old. We observed
a decrease in low-risk HPV infections with age, a finding
that has been confirmed by other studies [54-56]. This
decrease is consistent with the scant capacity of these
genotypes to circumvent human defences. Several stud-
ies have reported a lower rate of persistence of infections
by low-risk genotypes than of infections by high-risk
types, suggesting that high-risk genotypes may more ef-
fectively evade the immune response and persist for a
longer time in the human body [57-59]. Indeed, Franco
et al. found that the mean duration of infections was 8.2
and 13.5 months for non-oncogenic and oncogenic
types, respectively [60]. Moreover, in a study conducted
on female university students, Richardson et al. found
that infection by HPV-16 was the most persistent (mean
duration 18.3 months), while HPV-6 displayed the short-
est mean duration (< 10 months) [61]. The ability of
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high-risk HPV types to persist for a longer time in the
host could be linked to the increase in the prevalence of
high-risk HPV genotypes with age in our study.
Regarding the estimated cumulative proportions of young
females without cervical lesions who were free from any
HPV infection at each age, it is interesting that 49.8% of
subjects were free from any HPV infection at the age
of 26 years (Figure 4). Furthermore, if we consider the
estimated cumulative proportions of females free from
high-risk vaccine HPV infection at each age, 93.3% of 26-
year-old women proved to be free from HPV-16 and/or
HPV-18 (Figure 5A). Since the currently available HPV vac-
cines have shown partial cross-protection against high-risk
oncogenic types [24,25], we also calculated the cumulative
proportion of women free from infection by apha7/apha9
high-risk HPV species. At the age of 26 years, 92.2% and
84.7% of women, respectively, were also free from these in-
fections (Figure 5B and 5C). In addition, at the age of
26 years, 97.1% of the women studied were free from infec-
tion by types 6 and 11 (Figure 5D).
In Italy, HPV vaccination has been offered free of
charge to 12-year-old females since 2008, and both the
quadrivalent and the bivalent vaccine are available. More
recently, some Italian Regions have extended free vac-
cination to other female cohorts. Although the Italian
Ministry of Health initially recommended vaccination
for women aged 25–26 years, too [62], most Italian Re-
gions offer vaccination free of charge only to younger
women, with the aim of obtaining the maximum cost/ef-
fect benefit of vaccination in terms of public health [63].
The Italian strategy is similar to the strategies adopted
by other developed countries and the member states of
the European Union, despite obvious differences [30,64].
In this perspective, our study suggests that vaccinating
females without cervical lesions up to 26 years of age ap-
pears to be useful both from the point of view of public
health and from the point of view of the individual
health of the women. Furthermore, studies on HPV vac-
cines have demonstrated that vaccination is effective, al-
beit to different degrees, both in naïve females and in
women with evidence of prior HPV exposure [25].
Our considerations regarding the need to extend free vac-
cination to women up to 26 years of age are supported by
epidemiological and economic studies. Epidemiological
studies have shown that the risk of HPV infection remains
in older age-groups; indeed, all sexually active women are
exposed to the risk of infection at any age [27,65]. A meta-
analysis on worldwide HPV prevalence in women with nor-
mal cytology has shown that HPV prevalence is high up to
34 years of age, subsequently decreases up to the age of
44 years, and then tends to rise again in older age-groups
[27]. Moreover, economic evaluations also support the util-
ity of extending free vaccination to women up to 26 years
of age. Indeed, a study conducted in Italy has reported that
vaccinating 25-year-old women is cost-effective, and that
this strategy, in comparison with screening alone, could
avoid 696 cases of cervical cancer, 11,000 cases of CIN1
and 1,500 cases of CIN2/3 [65]. Furthermore, Westra et al.
developed a Markov model to estimate the age-specific
health benefits and cost-effectiveness of vaccination in the
Netherlands; they conclude not only that vaccinating girls
against HPV before their sexual debut is a highly effective
and cost-effective strategy for the prevention of cervical
cancer, but also that vaccination of women up to the age of
25 years is generally cost-effective [66]. Finally, a review that
reports the evidence for the dual approach of HPV vaccin-
ation and HPV-based cervical screening has reported that
HPV vaccination is likely to provide additional protection
to women under the age of 30 years [67].
Conclusions
Our study confirms the importance of type 16 in both
single and multiple infections and highlights the import-
ance of type 52, which was second only to type 16 in
women without cytological damage. Furthermore, it con-
firms the crucial importance of conducting studies on
women without cytological damage, in order to optimise
and up-date preventive interventions against HPV infec-
tion, such as vaccination.
Our findings also emphasize the importance of vaccinat-
ing young women up to 18 years of age through catch-up
campaigns. Furthermore, they suggest the utility of updating
vaccination strategies so as to include women up to 26 years
of age, while taking the opportunity to perform a Pap test at
the time of administering the first dose of vaccine. Never-
theless, this strategy should be further explored. This strat-
egy could help to achieve good coverage, raise awareness of
cervical cancer prevention and monitor the effectiveness of
the vaccine at subsequent screening visits.
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